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Abstract
Background: A fundamental goal of the U.S. National Institute of Health (NIH) "Roadmap" is to strengthen Translational
Research, defined as the movement of discoveries in basic research to application at the clinical level. A significant barrier
to translational research is the lack of uniformly structured data across related biomedical domains. The Semantic Web
is an extension of the current Web that enables navigation and meaningful use of digital resources by automatic
processes. It is based on common formats that support aggregation and integration of data drawn from diverse sources.
A variety of technologies have been built on this foundation that, together, support identifying, representing, and
reasoning across a wide range of biomedical data. The Semantic Web Health Care and Life Sciences Interest Group
(HCLSIG), set up within the framework of the World Wide Web Consortium, was launched to explore the application
of these technologies in a variety of areas. Subgroups focus on making biomedical data available in RDF, working with
biomedical ontologies, prototyping clinical decision support systems, working on drug safety and efficacy communication,
and supporting disease researchers navigating and annotating the large amount of potentially relevant literature.
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Results: We present a scenario that shows the value of the information environment the Semantic Web can support
for aiding neuroscience researchers. We then report on several projects by members of the HCLSIG, in the process
illustrating the range of Semantic Web technologies that have applications in areas of biomedicine.
Conclusion: Semantic Web technologies present both promise and challenges. Current tools and standards are already
adequate to implement components of the bench-to-bedside vision. On the other hand, these technologies are young.
Gaps in standards and implementations still exist and adoption is limited by typical problems with early technology, such
as the need for a critical mass of practitioners and installed base, and growing pains as the technology is scaled up. Still,
the potential of interoperable knowledge sources for biomedicine, at the scale of the World Wide Web, merits
continued work.
Background
Translational research and the information ecosystem
Starting in 2002, the NIH began a process of charting a
"roadmap" for medical research in the 21st century [1],
identifying gaps and opportunities in biomedical research
that crossed the boundaries of then extant research insti-
tutions. A key initiative that came out of this review is a
move to strengthen Translational Research, defined as the
movement of discoveries in basic research (the Bench) to
application at the clinical level (the Bedside).
Much of the ability of biomedical researchers and health
care practitioners to work together – exchanging ideas,
information, and knowledge across organizational, gov-
ernance, socio-cultural, political, and national boundaries
– is mediated by the Internet and its ever-increasing digital
resources. These resources include scientific literature,
experimental data, summaries of knowledge of gene prod-
ucts, diseases, and compounds, and informal scientific
discourse and commentary in a variety of forums.
Together this information comprises the scientific "infor-
mation ecosystem" [2]. Despite the revolution of the Web,
the structure of this information, as evidenced by a large
number of heterogeneous data formats, continues to
reflect a high degree of idiosyncratic domain specializa-
tion, lack of schematization, and schema mismatch.
The lack of uniformly structured data affects many areas of
biomedical research, including drug discovery, systems
biology, and individualized medicine, all of which rely
heavily on integrating and interpreting data sets produced
by different experimental methods at different levels of
granularity. Complicating matters is that advances in
instrumentation and data acquisition technologies, such
as high-throughput genotyping, DNA microarrays, pro-
tein arrays, mass spectrometry, and high-volume ano-
nymized clinical research and patient data are resulting in
an exponential growth of healthcare as well as life science
data. This data has been provided in numerous discon-
nected databases – sometimes referred to as data silos. It
has become increasingly difficult to even discover these
databases, let alone characterize them.
Together, these aspects of the current information ecosys-
tem work against the interdisciplinary knowledge transfer
needed to improve the bench-to-bedside process.
Curing and preventing disease requires a synthesis of 
understanding across disciplines
In applying research to cure and prevent diseases, an inte-
grated understanding across subspecialties becomes
essential. Consider the study of neurodegenerative dis-
eases such as Parkinson's Disease (PD), Alzheimer's Dis-
ease (AD), Huntington's Disease (HD), Amyotrophic
Lateral Sclerosis (ALS), and others. Research on these dis-
eases spans the disciplines of psychiatry, neurology,
microscopic anatomy, neuronal physiology, biochemis-
try, genetics, molecular biology, and bioinformatics.
As an example, AD affects four million people in the U.S.
population and causes great suffering and incurs enor-
mous healthcare costs. Yet there is still no agreement on
exactly how it is caused, or where best to intervene to treat
it or prevent it. The Alzheimer Research Forum records
more than twenty seven significant hypotheses [3] related
to aspects of the etiology of AD, most of them combining
supporting data and interpretations from multiple bio-
medical specialist areas.
One recent hypothesis on the cause of AD [4] illustrates
the typical situation. The hypothesis combines data from
research in mouse genetics, cell biology, animal neuropsy-
chology, protein biochemistry, neuropathology, and
other areas. Though commensurate with the "ADDL
hypothesis" of AD etiology [5], essential claims in Lesné et
al. conflict with those in other equally well-supported
hypotheses, such as the amyloid cascade [6] and alterna-
tive amyloid cascade [7].
Consider also HD an inherited neurodegenerative disease.
Although its genetic basis is relatively simple and it has
been a model for autosomal dominant neurogenetic dis-
orders for many years, [8], the mechanisms by which the
disorder causes pathology are still not understood. In the
case of PD, despite its having been studied for many dec-
ades, there are profound difficulties with some of theBMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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existing treatments [9,10], and novel or modified treat-
ments are still being developed [11,12].
Increasingly, researchers recognize that Ad, PD, and HD
share various features at the clinical [13], neural [14-17],
cellular [18-20], and molecular levels [21,22]. Nonethe-
less, it is still common for biologists in different subspe-
cialties to be unaware of the key literature in one another's
domain.
These observations lead us to a variety of desiderata for
the information environment that can support such syn-
thesis. It should take advantage of the Web's ability to ena-
ble dissemination of and access to vast amounts of
information. Queries need to be made across experimen-
tal data regardless of the community in which it origi-
nates. Making cross-disease connections and combining
knowledge from the molecular to the clinical level has to
be practical in order to enable cross-disciplinary projects.
Both well-structured standardized representation of data
as well as linking and discovery of convergent and diver-
gent interpretations of it must be supported in order to
support activities of scientists and clinicians. Finally, the
elements of this information environment should be
linked to both the current and evolving scientific publica-
tion process and culture.
The Semantic Web
The Semantic Web [23,24] is an extension of the current
Web that enables navigation and meaningful use of dig-
ital resources by automatic processes. It is based on com-
mon formats that support aggregation and integration of
data drawn from diverse sources.
Currently, links on Web pages are uncharacterized. There
is no explicit information that tells a machine that the
mRNA described by <ahref="/entrez/
viewer.fcgi?val=NM_000546.2"> on the Entrez page
about Human TP53 gene [25] is related to TP53 in any
specific way. By contrast, on the Semantic Web, the rela-
tionship between the gene and the transcribed mRNA
product would be captured in a statement that identifies
the two entities and the type of the relationship between
them. Such statements are called "triples" because they
consist of three parts – subject, predicate, and object. In this
case we might say that the subject is human TP53 gene, the
predicate (or relationship) hasGeneProduct, and the object
human TP53 MRNA. Just as the subject and object – the
pages describing the gene and mRNA – are identified by
Uniform Resource Identifiers (URIs) [26], so, too, is the
relationship, the full name of which might be http://
www.ncbi.nlm.nih.gov/entrez/hasGeneProduct. A Web
browser viewing that location might show the human
readable definition of the relationship.
Since URIs can be used to describe names, all information
accessible on the Web today can be part of statements in
the Semantic Web. If two statements refer to identical
URIs, this means that their subjects of discourse are iden-
tical. This makes it possible to merge data references. This
process is the basis of data and knowledge integration on
the Semantic Web.
With this as a foundation, a number of existing
approaches for organizing knowledge are being adapted
for use on the Semantic Web. Among these are thesauri,
ontologies, rule systems, frame based representation sys-
tems, and various other forms of knowledge representa-
tion. Together, the uniform naming of elements of
discourse by URIs, the shared standards and technologies
around these methods of organization, and the growing
set of shared practices in using those, are known as
Semantic Web technologies.
The formal definition of relations among Web resources is
at the basis of the Semantic Web. Resource Description
Framework (RDF) [27], is one of the fundamental build-
ing blocks of the Semantic Web, and gives a formal speci-
fication for the syntax and semantics of statements
(triples). Beyond RDF, a number of additional building
blocks are necessary to achieve the Semantic Web vision.
￿ The specification of a query language, SPARQL [28], by
which one can retrieve answers from a body of statements.
￿ Languages to define the controlled vocabularies and
ontologies that aid interoperability; the RDF Schema
(RDFS) [29], Simple Knowledge Organization System
(SKOS) [30], and the Web Ontology Language (OWL)
[31].
￿ Tools and strategies to extract or translate from non-RDF
data sources to enable their interoperability with data
organized as statements. For example, GRDDL (Gleaning
Resource Descriptions from Dialects of Languages) [32]
defines a way of associating XML with a transformation
that turns it into RDF. There are also a variety of RDF
extraction tools and interfaces to traditional databases
[33].
Specifications of some of these technologies have pub-
lished and are stable, while others are still under develop-
ment. RDF and OWL are about three years old, a long time
on the Web scale, but not such a long time for the devel-
opment of good tools and general acceptance by the tech-
nical community. Other technology specifications (SKOS,
GRDDL, SPARQL, etc.) will only be published as stand-
ards in the coming years – though usable implementa-
tions already exist.BMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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Despite the youth of these technologies, active developer
and scientific communities have developed around these
technologies e.g. SemWebCentral [34]. Today, there are a
large number of tools, programming environments, spe-
cialized databases, etc (see, e.g., [35]). These tools are
offered both by the open source community and as prod-
ucts offered by small businesses and large corporations.
Today, we are at the point at which anybody can start
developing applications for the Semantic Web because the
necessary development tools are now at our disposal.
How can the Semantic Web help biomedical research?
We have come to believe the judicious application of
Semantic Web technologies can lead to faster movement
of innovation from research laboratory to clinic or hospi-
tal. The Semantic Web approach offers an expanding mix
of standards, technologies, and social practices layered on
top of the most successful information dissemination and
sharing apparatus in existence – the World Wide Web.
Some of the elements of the technology most relevant to
biomedical research include:
The global scope of identifiers that follow from the use
of URIs offer a path out of the complexities caused by the
proliferation of local identifiers for entities of biomedical
interest. Too much effort has been spent developing serv-
ices mapping between, for instance, the gene identifiers
used by the many data sources recording information
about them.
The Semantic Web schema languages, RDFS and OWL,
offer the potential to simplify the management and com-
prehension of a complicated and rapidly evolving set of
relationships that we need to record among the data
describing the products of the life and medical sciences.
Along with the benefits of the technologies that underlie
our current data stores, there are a number of significant
disadvantages that the Web schema languages remediate.
RDFS and OWL are self-descriptive. Scientists that inte-
grate different types of data need to understand both what
the data means at the domain level, as well as the details
of its form as described in associated data schemas.
Because these schemas tend to be technology and vendor
specific, it is a significant burden to understand and work
with them. While the need to integrate more types of data
will continue, RDFS and OWL offer some relief to the bur-
den of understanding data schemas. On the Semantic
Web, classes and relationships are represented in the same
way as the data. Documentation about them is uniformly
discoverable due to the standardized rdf:comment prop-
erty. In a well-designed ontology, the structure itself can
often help guide users towards its correct use. Some exam-
ples of such structure are the well defined meaning of the
hierarchical subclass relations, the use of properties
defined by the ontology in the construction of definitions
within the ontology, and a carefully designed modulariza-
tion [36].
RDFS and OWL are flexible, extendable, and decentral-
ized because they are designed for use in the dynamic,
global environment of the Web. RDFS and OWL support
hierarchical relationships at their core, allowing for easy
incorporation of subclass and subproperty relationships
that are essential for managing and integrating complex
data. New schemas can easily incorporate previously
defined classes and properties that refer to data elsewhere
on the Web without the all-too-typical copying and local
warehousing of data to be built upon. When different
schemas are found to have classes or properties that
describe the same kinds of data or relationships, state-
ments may be added that formally record that they should
be considered the same. This allows for simpler queries
that do not have to account for those equivalences.
The ability to easily extend the work of others makes
worthwhile the development of ontologies that can be
shared across different domains. For example, there are
recent efforts to develop middle ontologies, such as EXPO
[37] and the Ontology for Biomedical Investigations
(OBI) [38], that are designed to model scientific experi-
ments and investigations. Data from projects that build
upon them will be easier to link together than those that
use ad-hoc solutions or choose from a variety of disparate
and sometimes proprietary LIMS (Laboratory Informa-
tion Management Software) systems.
Reasoners for the Semantic Web schema languages intro-
duce capabilities previously not widely available by offer-
ing the ability to do inference, classification, and
consistency checking. Each of these capabilities has ben-
efits across the health care and life science domains. For
example, the powerful consistency checking offered by
OWL reasoners can help ensure that schemas, ontologies,
and data sets do not contain contradictory or malformed
statements. These erroneous statements are unfortunately
quite common. For example, in ongoing work merging
two E. coli metabolic databases, 120 cross reference errors
were found when comparing descriptions of several hun-
dred metabolites described in both [39]. In a review of
Gene Ontology (GO) term usage, up to 10% of terms used
for gene annotations were obsolete [40]. When present in
research data such errors can lead to missed opportunities.
When present in medical records they can result in inap-
propriate diagnosis and treatment.
We envision the use of Semantic Web technologies will
improve the productivity of research, help raise the qual-
ity of health care, and enable scientists to formulate new
hypotheses inspiring research based on clinical experi-BMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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ences. To help realize this vision, the World Wide Web
Consortium (W3C) established the Semantic Web Health
Care and Life Sciences Interest Group (HCLSIG) [41]
which is chartered to explore and support the use of
Semantic Web technologies to improve collaboration,
research and development, and innovation in the infor-
mation ecosystem of the health care and life science
domains.
In the remainder of this paper we will describe the
makeup and activities of HCLSIG, present a motivating
scenario, describe efforts and issues encountered as we
have explored the use of Semantic Web technologies, and
discuss challenges to and prospects for the approach.
Methods
The HCLSIG
The HCLSIG is intended to serve as a bridge connecting
the Semantic Web community's technology and expertise
to the information challenges and experiences in the
health care and life science communities. It pulls together
scientists, medical researchers, science writers, and infor-
maticians working on new approaches to support bio-
medical research. Current participants come from
academia, government, non-profit organizations, as well
as healthcare, pharmaceuticals, and industry vendors. The
ultimate goal is that collaboration between all four groups
will help facilitate the development of future standards
and tools. Indeed, one objective of a Semantic Web will be
to support the effective interaction between academia and
industry.
The HCLSIG's role in the effort to create the bench-to-bed-
side model is to experiment with the application of such
standards-based semantic technologies in working with
biomedical knowledge. A primary goal is to enable the
dynamic "recombining of data", while preserving the lay-
ers of meaning contributed by all the participating
research groups.
The group's scope is for two years, continuing through the
end of 2007. It was chartered with three specific objectives
in the domain of Health Care and Life Sciences.
￿ Identification of core vocabularies and ontologies to
support effective access to knowledge and data.
￿ Development of guidelines and best practices for unam-
biguously identifying resources such as medical docu-
ments and biological entities.
￿ Development of proposals and strategies for directly and
uniformly linking to the information discussed in scien-
tific publications from within those publications – for
example the data, protocols, and algorithms used in the
research.
The HCLSIG adopts a community-based approach to fos-
tering discussions, exchanging ideas, and developing use
cases. It also facilitates collaboration among individual
members. In addition to using a public mailing list (pub-
lic-semweb-lifesci@w3.org) to broadcast and exchange
email messages, the HCLSIG conducts regular teleconfer-
ence calls for members to participate. Wiki pages have
been created [42] for describing the various activities in
progress within HCLSIG, sharing data and documents
produced by individual projects and writing documenta-
tion in a collaborative fashion. Face-to-face meetings took
place in the United States and The Netherlands to engage
the HCLSIG members in closer and more personal inter-
actions as well as working sessions. As a result of the activ-
ities from the face-to-face meeting in January 2006, five
task forces were established. Each task force plans its work
within the two year overall timeframe. The task forces
independently, and sometimes collectively, work on dif-
ferent aspects of the overall challenge. These task forces
and their goals are described below.
BioRDF
Existing biomedical data is available in different (non-
Semantic-Web) formats including structured flat files,
HTML, XML and relational databases. Often these formats
include elements or fields, which are natural language.
BioRDF has the goal of converting a number of publicly
available life sciences data sources into RDF and OWL.
Heterogeneous data sources have been selected so that the
group can explore the use of a variety data conversion
tools, thereby gaining insight into the pros and cons of
different approaches.
Ontologies
A goal of the HCLSIG is to facilitate creation, evaluation
and maintenance of core vocabularies and ontologies to
support cross-community data integration and collabora-
tive efforts. Although there has been substantial effort in
recent years to tackle these problems, the methodology,
tools, and strategies are not widely known to biomedical
researchers. The role of the ontologies task force is to work
on well-defined use cases, supporting the other HCLSIG
working groups. Where possible, the group works to iden-
tify ontologies that formalize and make explicit the key
concepts and relationships that are central to those use
cases. In cases where ontologies do not currently exist, the
group works on prototyping and encouraging further
development of the necessary terminology.
Drug safety and efficacy
The development of safe and efficacious drugs rests on the
proper and timely utilization of diverse information setsBMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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and the adoption of and compliance to well-defined pol-
icies. The group works on the evaluation of Semantic Web
technologies in a number of areas, focusing on the use of
ontologies to aid queries against the different information
sets, and rules for specification of policies. Topics include:
￿ Identifying and addressing challenges working with
biomarkers and pharmacogenomics in coordination with
U.S. Food and Drug Administration (FDA) and European
Medicine Agency (EMEA) guidelines.
￿ Detecting, examining, and classifying signals of poten-
tial drug side-effects or adverse reactions [43,44].
￿ Issues in clinical trial planning, management, analysis,
and reporting – e.g., data security and integrity.
￿ Facilitating electronic submissions as per the Common
Technical Document [45] specifications.
Adaptable clinical pathways and protocols (ACPP)
Evidence based clinical guidelines and protocols are rec-
ommendations for diagnostic and therapeutic tasks in a
health care setting. They are increasingly perceived as an
important vehicle for moving results of research and clin-
ical trials to application in patient care. Much effort has
been devoted to representing clinical guidelines and pro-
tocols in a machine-executable format [46]. This has
proven to be quite a challenge. Translating the text-based
guidelines to a machine-executable format is costly and
thus far, solutions have required proprietary guideline
execution engines, limiting widespread adoption. The
slow pace of updating such guidelines limit their use in
medical practices that want to quickly incorporate new
clinical knowledge as it is published.
The ACPP task force explores the use of Semantic Web
technologies, including RDF, OWL, logic programming,
and rules to represent clinical guidelines and guide their
local adaptation and execution. Guidelines encoded using
these technologies can be accessed, reasoned about, and
acted upon by a clinical information system. Since guide-
lines are Web documents, they have the potential to be
more rapidly updated.
The following aspects of guideline and protocol represen-
tation and reasoning are of special interest:
￿ Inclusion and exclusion criteria that are used to decide
whether evidence suggests the use of a particular guideline
or protocol.
￿ Representation of temporal concepts and inference rules
necessary for tracking processes and ensuring temporal
constraints on treatment.
￿ Representation of medical intentions, goals, and out-
comes.
￿ Use of logic programming to implement guidelines
adaptable to site of care execution constraints and changes
in patient condition.
Scientific publishing
Today, a large portion of biomedical knowledge produc-
tion is in the form of scientific publications. Most often,
on the Web, these publications are referred to either by
name or by using hyperlinks. Neither the relationship of
the publication to the context from which it is cited, nor
the entities and relationships described by it, are explicitly
represented. The scientific publishing task force is
involved in several activities aimed at ameliorating this
situation, attentive to the importance of social process
and community engagement.
￿ Developing an application enabling researchers to col-
lect publications, annotate, and interrelate the hypotheses
and claims they present, and share their collections.
￿ Applying natural language processing techniques to sci-
entific text to recognize and encode entities and relation-
ships among them.
￿ Creating prototypes of tools and processes to enable
researchers to include such information as a standard part
of the scientific publication process.
Neuromedicine and the semantic web
From the outset, HCLSIG participants felt strongly that
useful application of Semantic Web to biomedicine
would only occur if the technology was applied to and
rooted in realistic use cases, and if the various task forces
were encouraged to have their work interoperate within a
common domain. Although medical research and prac-
tice generally depend on data sets covering genetics to
clinical outcomes, research in and therapy development
for the neurodegenerative disorders is a particularly strik-
ing illustration of the need for active, ongoing, synthesis
of information, data, and interpretation from many
sources and subdisciplines in biomedicine. For this rea-
son, the HCLSIG is currently exploring use cases involving
neurodegenerative diseases such as PD and AD. Next, we
illustrate some of the issues with a scenario of a clinical
researcher attempting to develop immunotherapies for
AD.
Alzheimer's disease immunotherapy scenario
A scientist working in a research hospital is pursuing
immunization therapy for AD. A clinical trial of a vaccine
made of synthetic Abeta1-42 ended prematurely a few
years ago because 15 volunteers developed cerebralBMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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inflammation [47]. However, the field remains enthusias-
tic about new immunization strategies to reduce Abeta in
early Alzheimer's, believed to be the culprit of AD [48],
and to study the mechanism of action of Abeta immuni-
zation [49]. Important steps would be to identify the spe-
cific form of Abeta that is toxic to neurons and/or other
elements critical to proper CNS function, and the mecha-
nism of its toxicity.
The scientist uses her local scientific knowledge manage-
ment system (sci-know) to search the Alzheimer Research
Forum Web site and finds a recently published hypothesis
(Abeta*56 Hypothesis) claiming a newly identified assem-
bly of amyloid beta peptide, Abeta*56, causes memory
impairment [4]. However, the hypothesis is based on
claims only supported by experimental results from a
transgenic mouse model. She wonders if Abeta*56 is
found in actual AD patients, particularly in the early
stages.
Based on the terms tagged to the hypothesis, that along
with the original citation have been added to sci-know, the
investigator constructs a search adding the concept human
to the original query. The new query is run against
PubMed and the hypothesis repository. Drawing on the
ontology in the vicinity of the search terms to cluster the
results, one research article comes to the forefront:
i. Using a novel, attomolar detection system, Amyloid-
beta Derived Diffusable Ligands (ADDL) are elevated
8-fold on average (max 70-fold) in the cerebrospinal
fluid of patients with AD [50].
The Alzforum AD Hypothesis knowledgebase shows (i) is
cited as supportive evidence for the ADDL Hypothesis
claiming  ADDL causes memory impairment. Though the
Abeta*56 hypothesis does not yet include a proposed
mechanism for memory loss in the mouse model, the
ADDL hypothesis includes a finding that ADDLs bind to
human-derived cortical synaptic vesicles [51], and they
inhibit hippocampal long-term potentiation (LTP) [52], a
form of synaptic plasticity known to be critical for certain
forms of learning and believed to be equally critical for
memory storage [53,54]. Additional supporting evidence
cited for this hypothesis notes Abeta alters A-type K+
channels involved in learning and memory, leading to
altered neuronal firing properties as a prelude to cell death
in Drosophila cholinergic neurons [55]. This provides a
possible mechanistic explanation for the demonstrated
learning disabilities, memory dysfunction, and neurode-
generation in transgenic Drosophila expressing human
Abeta [56].
Are these model organism findings relevant to patients
with AD? The researcher wonders whether A-type K+
channels are plausible therapeutic targets for treating
patients diagnosed with AD. She asks:
"Show me the neuron types affected by early AD."
The sci-know system searches the Alzforum and comes up
with several instances of neuronal cell types damaged in
AD. These include BDNF neurons of the nucleus basalis of
Meynert [57,58] and CA1 pyramidal neurons of the hip-
pocampus [59]. Next, the researcher asks:
"Do BDNF neurons or CA1 pyramidal neurons have A-
type K+ channels?"
"Are there other studies relating amyloid derived peptides
to neocortical K+ channels?"
The application returns results from a neuropharmacolog-
ical knowledgebase, BrainPharm. [60]. BrainPharm indi-
cates CA1 pyramidal cells have A-type potassium
channels. Interestingly, this finding carries the following
annotation:
"Application of beta-amyloid [Abeta] to outside-out
patches reduces the A-current; leading to increased den-
dritic calcium influx and loss of calcium homeostasis,
potentially causing synaptic failure and initiating neuro-
nal degenerative processes." [61].
Our researcher wonders whether the 56 kD form of Abeta
is responsible for this effect and is led to a series of scien-
tific questions she would like to address in her lab. Would
the Tg2576 mouse model, the one in which Abeta*56 was
reported to correlate with memory impairment, have a
reduced A-current? Would blocking Abeta*56 with an
antibody restore the A-current level? Our researcher types
in one more query:
"Is there an antibody to Abeta*56 or ADDL?"
The application searches across a number of antibody
resources and identifies one in another researcher's shared
antibody database that even lists the e-mail address of the
laboratory where she can obtain the antibody.
Making data available in RDF and OWL
In our scenario, a number of queries are posed for a vari-
ety of types of biomedical knowledge. We query for spe-
cific types of neurons, the types of their associated ion
channels, for the properties of amyloid derived peptides
and their molecular interactions, for hypotheses and dis-
cussions about them, and for antibody reagents. Much,
but not all, of this information is available in publicly
accessible data sets. However, in order for them to be used
on the Semantic Web, they need to be made accessible asBMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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RDF or OWL. The BioRDF group is exploring a number of
methods for doing this. Among the data sets we have con-
verted, and plan to make publicly available, are:
￿ SenseLab.  The subset of SenseLab  [62] that contains
information about pathological mechanisms related to
Alzheimer's Disease (BrainPharm) has been converted
into RDF and the subset containing information about
neuronal properties (NeuronDB) has been converted into
OWL.
￿ CoCoDat. CoCoDat [63] is repository of quantitative
experimental data on single neurons and neuronal micro-
circuitry A subset of information about ionic currents in
different types of neurons has been converted into OWL.
￿  Entrez Gene. As described in [64], the Entrez Gene
repository of gene-centered information was converted in
its entirety to RDF.
￿ PDSP Ki DB. The PDSP Ki Database [65] is a repository
of experimental results about receptor-ligand interactions
and has a strong emphasis on neuroreceptors. It has been
converted into OWL that conforms to an extended version
of the established BioPAX [66] ontology for biomedical
pathways.
￿  BIND. The Biomolecular Interaction Network Database
(BIND) [67] is a large collection of molecular interactions,
primarily protein-protein interactions. Like the PDSP
KiDB, the OWL version of BIND is based on the BioPAX
ontology.
￿ Antibodies – A collection of commercial antibody rea-
gent data derived from the Alzforum Antibody Directory
[68] and by crawling reagent vendor sites has been ren-
dered in OWL.
In addition to the RDF and OWL data sets produced by
the HCLSIG participants, there is a growing collection of
RDF and OWL data sets that have been made available.
Among these data sets are the OBO ontologies [69], Reac-
tome [70], KEGG [71], NCI Metathesaurus [72], and Uni-
Prot [73].
Below we briefly discuss three approaches we have used to
make data sets available in RDF.
CoCoDat
D2RQ [74] is used to provide access to CoCoDat. D2RQ
is a declarative language to describe mappings between
relational database schemas and either OWL or RDFS
ontologies. The mappings allow RDF applications to
access the contents of relational databases using Semantic
Web query languages like SPARQL. Doing such a map-
ping requires us to choose how tables, columns, and val-
ues in the database map to URIs for classes, properties,
instances, and data values. We illustrate some of these
considerations by walking through a portion of the D2RQ
document describing the mapping of CoCoDat's rela-
tional database form to RDF. In it, we see how rows in the
Neurons  table are mapped to instances, the column
ID_BrainRegion is mapped to a property, and the string
values of that column are mapped to URIs.
@prefix d2rq: http://www.wiwiss.fu-berlin.de/suhl/
bizer/D2RQ/0.1#.
@prefix: http://semweb.med.yale.edu/NeuroWeb/
owl/cocodat#.
@prefix db1: http://semweb.med.yale.edu/Neu-
roWeb/db/cocodat#.
The first task is to define the namespace bindings [75]. A
namespace binding associates an abbreviation with a pre-
fix used for a set of URIs. Following Semantic Web prac-
tice, all identifiers used in the mapping description are
URIs. The mapping needs to use identifiers defined by
D2RQ, identifiers we will generate for the RDF version of
CoCoDat, and identifiers for parts of the relational data-
base.
￿ "d2rq:" is the abbreviation for the namespace of identi-
fiers used by D2RQ.
￿ "db1:" is the abbreviation for the namespace of identifi-
ers of parts of the relational database.
￿ As identifiers should be globally unique, and the group
undertaking the translation controls the domain
'semweb.med.yale.edu', the namespace for new identifiers
in the RDF version of CoCoDat is based on that domain.
This is chosen to be the default namespace, abbreviated as
":".
db1:CoCoDatDB rdf:type d2rq:Database; d2rq:odb-
cDSN "cocodat";
Now the relational database where CoCoDat is stored is
identified as "db1:CoCoDatDB" and defined by its con-
nection via ODBC.
db1:RecordingNeuronSite rdf:type d2rq:ClassMap;
d2rq:class :RecordingNeuronSite;
d2rq:uriPattern ":RecordingNeuronSite-@@Neu-
rons.ID@@";BMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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d2rq:dataStorage db1:CoCoDatDB.
Following that, each row of the database table Neurons is
mapped to an instance of the OWL class called :Recording-
NeuronSite. The URI of each instance is constructed using
the primary key of the table, ID. Therefore, the instance
with the primary key 1 will have the URI "http://
semweb.med.yale.edu/NeuroWeb/owl/cocodat#Record-
ingNeuronSite-1", abbreviated :RecordingNeuronSite-1.
db1:inBrainRegion rdf:type d2rq:ObjectProperty-
Bridge;
d2rq:belongsToClassMap db1:RecordingNeuronSite;
d2rq:property :inBrainRegion;
d2rq:pattern "@@Neurons.ID_BrainRegion@@";
d2rq:translateWith db1:BrainRegionTable.
In this step, the ID_BrainRegion column in the Neuron
table is mapped to the property :inBrainRegion. The values
of that column are not to be used directly, instead under-
going a translation that is defined next.
db1:BrainRegionTable rdf:type d2rq:TranslationTa-
ble;
d2rq:translation [d2rq:databaseValue "GM-Ctx_B";
d2rq:rdfValue :barrel-cortex;];
d2rq:translation [d2rq:databaseValue "GM-Ctx_Gen";
d2rq:rdfValue :general-cortex;];
d2rq:translation [d2rq:databaseValue "GM-Ctx_SeM";
d2rq:rdfValue :sensorimotor-cortex;];
In this last step, we see a portion of the mapping of values
from the ID_BrainRegion column. The string values in
this column are meant to represent brain regions. Know-
ing that it is likely these values will need to be equated
with terms from other ontologies, a decision is made to
represent them as URIs. Later, one will be able to use
owl:sameAs to equate these terms with others. With this
mapping, the string "GM-Ctx_B" is translated into the URI
"http://semweb.med.yale.edu/NeuroWeb/owl/coco-
dat#barrel-cortex".
The result of this mapping specification will be the crea-
tion of statements such as <:RecordingNeuronSite-
1><:inBrainRegion><:barrel-cortex>, assuming the ID of
the first row of the Neurons table is 1 and the value in the
ID_BrainRegion column is "GM-Ctx_B".
Entrez Gene
The XML version of Entrez Gene was transformed to RDF
using XSLT [76]. The XML source is 50 GB and the gener-
ated RDF consists of 411 million triples. The Oracle Data-
base 10g RDF Data Model was used to store and query the
data. Although it would have been expedient to use XML
element names directly as RDF properties, we instead
mapped the element names to property names that were
more descriptive and adhered better to accepted RDF
style. For example, the element Gene-track_geneid  was
changed to the property has_unique_geneid. An authorita-
tive URI naming scheme for NCBI resources does not
exist, so the namespace "http://www.ncbi.nlm.nih.gov/
dtd/NCBI_Entrezgene.dtd/" was created for use in this
prototype.
Antibodies. The curation of information about antibody
reagents is much less mature than that about genes and
many other biological entities. Therefore, creation of this
resource had a number of interesting problems. The most
difficult challenge was how to associate antibodies with
proteins. The query in our scenario depends on this asso-
ciation, yet the Alzforum directory and most commercial
reagent vendors do not associate antibody targets with
well known identifiers. Instead, they are listed by gene,
protein, or molecule name. Our focus was on antibodies
that react with proteins. Determining the referent of anti-
body names can be difficult because of the large number
of gene and protein synonyms. This is further complicated
because names can have variant spellings, antibodies can
be non-specific, vendors can use idiosyncratic names, and
protein names are often embedded in a product name.
Our approach was to collect gene and protein synonyms
from a variety of public databases – Entrez Gene, UniProt,
OMIM [77], and Enzyme [78]. Sets of transformation
rules (based on regular expressions) were applied to prod-
uct listings to extract protein names, normalize common
spelling variations, and recognize certain forms of lists.
Finally, only unambiguous matches to names were con-
sidered reliable enough to use.
Understanding the provenance and terms of usage of data
is important within science. We therefore created RDF
using the FOAF [79] vocabulary to describe the Alzforum
project, and used Dublin Core [80] properties to identify
usage policies for the data. This RDF was linked to the
newly compiled Alzforum antibody listing.
Curating and navigating disease hypotheses, claims, and 
evidence
In our scenario, an essential part of the navigation that
leads the scientist from desired therapy to molecular
mechanism is based on relationships between hypothe-
ses. Although much of what we represent in biomedical
databases are experimental measurements or observa-BMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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tions, the act of creating and consuming knowledge
occurs in a complex web of activities and relationships.
From this perspective, one way to view biomedical knowl-
edge is as an incomplete network whose "growing edges"
contain unresolved contradictions, i.e. varying interpreta-
tions of experimental data in relation to hypotheses.
A natural science focused ontology of AD might contain
the relationship <NeurofibrillaryTangle><locate-
dIn><Neuron>, asserting a known fact. However, for
active researchers in a field, many times the most interest-
ing relationships are those that that are just emerging, i.e.
they cannot yet be considered validated, and are often the
subject of scientific controversy. Perhaps more than any-
where, the collection of these hypotheses, claims, and dis-
putes characterizes the world of science and provides the
raw material propelling experiments, grants, and publica-
tions. How, then, can we assist scientists in taking advan-
tage of this class of knowledge?
SWAN (Semantic Web Applications in Neuromedicine),
developed in part by members of the HCLSIG, is an appli-
cation that focuses on enabling AD researchers to curate,
organize, annotate, and relate scientific hypotheses,
claims and evidence about the disease. The ultimate goal
of this project is to create tools and resources to manage
the evolving universe of data and information about AD,
in such a way that researchers can easily comprehend their
larger context ("what hypothesis does this support or con-
tradict?"), compare and contrast hypotheses ("where do
these two hypotheses agree and disagree?"), identify
unanswered questions, and synthesize concepts and data
into more comprehensive and useful hypotheses and
treatment targets for this disease.
The application is oriented towards use by both the indi-
vidual researchers and within the community. Therefore
the application supports both secure personal workspaces
as well as shared, public workspaces.
The 2005 pilot application was developed as a proof of
concept for hypothesis management [81]. In SWAN, per-
sonal and public knowledgebases are structured as RDF
triple stores manipulated by the Jena framework [82].
Content can be exported and shared peer-to-peer or via
public knowledge servers. Neuroscientists and scientific
editors have used the system. Knowledge in the work-
spaces has been integrated with data from SenseLab and
other data sets using the Oracle RDF Data Model [83,84].
Development continues and initial deployment will be as
part of the Alzheimer Research Forum Web site [85].
Working with clinical guidelines
Much effort has been devoted to representing clinical
guidelines and protocols in a machine-executable format
[46]. The high cost of creating these frameworks and the
specialized software needed to use them has hindered
wide adoption of such systems. One challenge is that the
encoded guidelines are not generally interoperable
between systems, diluting what could be a combined
effort to build this valuable resource. We observe that
much of the technology needed to represent and execute
such guidelines is available as part of the Semantic Web
stack. Thus, we are experimenting with using Semantic
Web technologies to implement such guidelines in order
to show their effectiveness and to give feedback to devel-
opers on where additional capabilities are needed. Work-
ing within the Semantic Web would benefit this field for
at least two reasons. First, the open standards for the tech-
nologies on which such systems can be built would
encourage researchers and vendors to build systems that
can interoperate. Second, it would speed development of
such systems by making it easier for them to incorporate
essential and current biomedical knowledge created by
others, saving the cost of encoding that knowledge in each
system that uses it.
Adaptability to changing conditions is an important
requirement for making clinical recommendations. These
changes take the form of a patient's condition progressing
in potentially unpredictable ways, and new medical
research and clinical trials that should be considered in
addition to established guidelines.
Within ACPP we have modeled guidelines as directed
graphs using RDF and OWL [86]. Within such a network,
each node is a task. Depending on the granularity desired
by clinical practices using the guideline, the task might be
a process or a set of processes. Each process is designed to
accomplish a clinical goal, such as acquiring knowledge
via a diagnostic test and is associated with its expected
outcome and a desired timeframe for that outcome. OWL
is used to represent the ontology of clinical goals and out-
comes following [87].
Each task has a context describing a set of sufficient condi-
tions that make the process worthy of recommendation
and safe to carry out. The context describes a mix of the
patient's clinical and physical conditions, treatment sta-
tus, and care setting. For example, it can make reference to
states of prior or parallel processes, such as whether they
were completed or aborted, and clinical settings such as a
long term care centre, or an emergency room. These con-
ditions are organized into inclusion and exclusion criteria.
Inclusion criteria may be weighted and a minimum sum
of weights of satisfied criteria is specified as a threshold
above which a task can be recommended.
As an example, consider the treatment of dementia in AD
patients. Prescription of cholinesterase inhibitors such asBMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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donepezil, rivastigmine, and galantamine are recom-
mended based on evidence from clinical trials [88]. In our
model, using OWL, prescribingCholinesteraseInhibitors is an
instance of the Process class. An inclusion criterion would
be a diagnosis of either AD Dementia, PD or Lewy Body
Dementia (DLB). These diagnoses are represented as
classes, and so the inclusion criterion can be represented
as an OWL union of the classes. Exclusion criteria would
be vomiting or other severe gastrointestinal disorders.
A clinical decision support system can recommend the
next task in a patient-specific pathway based on rules.
Although we have used OWL for evaluating rules using
instance classification, the current standard is not expres-
sive enough to use the weights and thresholds we assign
to criteria in class definitions. To implement the follow-
ing, we use Notation 3 [89] rules. All tasks are evaluated
in the following way to see which are candidates for rec-
ommendation.
￿ Query the healthcare information network for all past
and present patient conditions mentioned in the inclu-
sion or exclusion criteria.
￿ If any exclusion criteria hold then discard the task.
￿ Collect the satisfied inclusion criteria.
￿ Add the weights assigned to each satisfied inclusion cri-
teria.
￿ If the sum exceeds the threshold, the task may be recom-
mended.
Regular re-evaluation during periods of patient stability
and upon any change in medical condition allow us to
adapt the treatment plan to the current medical situation.
This approach to representing guidelines is also well
suited to the incorporation of new knowledge. Each
guideline would be available as an individual RDF or
OWL document uniquely identified by its URI. Trusted
sources would be identified that maintain up-to-date
guidelines and protocols. Analogous to the contexts  of
tasks, each guideline or clinical trial would be associated
with its own inclusion and exclusion criteria that would
qualify the whole body of knowledge, i.e. all tasks
described in the guideline. With this approach, the same
form of rules used to identify relevant tasks would be used
to identify relevant guidelines [90]. The tasks from all rel-
evant guidelines and protocols would then be evaluated
to determine the set of recommendations. By applying
this method, if a patient has multiple clinical conditions,
all relevant guidelines can be utilized to ensure doctors
have appropriate information to ensure the best possible
treatment for their patients.
Discussion
Data integration
There is a tacit assumption within the Semantic Web com-
munity that every data set and ontology will interoperate.
The reality is that different conceptualizations and repre-
sentations of the same data can exist. While the architec-
ture and basic tools of the Semantic Web remove a set of
previous roadblocks to data integration, positive progress
towards it requires study, experimentation, and at-scale
efforts that exercise proposed solutions.
To date, we have primarily focused on building proto-
types that have functioned independently. Much of the
RDF and OWL that has been generated mirrors the struc-
ture of the original data sets. Such translations are more
syntactic than semantic. Even so, the common syntax ena-
bles an easier creation of cross-domain queries. As an
example, in [83] the RDF translation of BrainPharm and
SWAN's publication, data in RDF format were loaded into
a single RDF store. Having both data sets available simul-
taneously allowed interesting new queries. For example,
one could retrieve commentary by Alzforum members on
articles that discussed drugs for which BrainPharm had
models about cellular mechanism of action. This type of
query succeeds because the two data sets being integrated
do not, for the most part, discuss the same type of entity.
In order to integrate data sets, one of two things must hap-
pen: either terms for entities and relationships must be
shared between the data sets (the data sets must be built
using a shared ontology) or concordances must be availa-
ble that relate terms in one data set to those in another.
Even when the ontology is shared, there is no guarantee
that integration will be successful. Consider the BioPAX
exchange format, an OWL-based ontology that provides a
common framework for the many data sources that are
repositories of information on cellular pathways. Despite
the common ontology, it remains difficult to query an
aggregation of different sources of BioPAX formatted data,
e.g., for interactions related to the glucose metabolism
pathway. This is because the terms shared among the data
sources (the ones defined in the BioPAX standard) do not
cover the scientific domain adequately to support such a
query.
Building such ontologies is hard. The ontologies task force
has therefore started focusing on identifying available
knowledge resources (e.g., thesauri, terminologies, ontol-
ogies) that cover the basic biomedical entities and rela-
tions required to formally represent well defined scenarios
like the one we present above.BMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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While concepts in evolving areas of research may be
incomplete, unclear, in transition or under dispute, there
are many important entities and relations upon which
most biomedical researchers and clinicians will agree.
Mitochondria are found inside viable eukaryotic cells, vol-
untary movement in humans requires functional innerva-
tion of skeletal muscles, etc.
Our first goal is to construct a skeleton ontology specify-
ing the required high-level biomedical domains, and,
then to determine which public resources provide the
required domain entities and relations along with clear
prose definitions of them. These textual definitions are
essential to guide curators and translators of data sets
towards consistent usage of terms. Where definitions that
we need do not exist in public resources, we will attempt
to define the terms and work with others in the biomedi-
cal ontology community to refine and formalize them.
For example, an important term in our scenario is Ion
Channel. In order to pose a query about ion channels and
retrieve information about A-type K+ channels, we need to
ensure that the definition is clear enough that competent
informaticians who are not necessarily domain experts
have enough hints to gather sufficient information to real-
ize that a K+ channel is an ion channel.
It is important that the same attention that is given to
identifying and defining classes is also given to defining
relationships (properties) [91]. There are fewer defini-
tions for such relationships, in public resources, than for
classes. For example, in order to record details of the
hypotheses in our scenario, we need to define the rela-
tionship between Abeta and development of symptoms of
AD. Therefore we might define "isAPeptideContributing-
CauseOf" to be "a potentially causal relationship between
peptides such as Abeta1-42, Abeta*56 and a disease such
as AD or a clinical condition such as Memory Impair-
ment". The definition notes the type of subject (peptide)
and object (clinical condition or disease) of the property
that will formally link, as domain and range of the prop-
erty, and then to classes in our ontology. This definition
will serve as our input to other communities working in
this domain – for example when we participate in an
upcoming workshop on clinical trial ontologies organized
by the National Center for Biomedical Ontology (NCBO)
[92].
Current technical limitations of semantic web
Semantic Web technologies are young. Gaps in standards
and implementations still exist and adoption is limited by
typical problems with early technology, such as the need
for a critical mass of practitioners and installed base, and
growing pains as the technology is scaled up. Some issues
that have affected the work of the HCLSIG are:
Scarcity of semantically annotated information sources
Although we have listed a number of public sources of
data that are available in RDF, most common sources of
data for bioinformatics are not currently in a RDF or OWL.
However, mapping tools such as D2RQ should lower the
barrier to making these data sets available.
Performance and scalability
RDF and OWL stores are slower than optimized relational
databases, but are improving steadily [93]. However, log-
ical reasoning over large or complex ontologies remains a
problem.
Representation of evidence and data provenance
It is often important to know where knowledge has come
from and how it has been processed. It is also useful to
know who believes something and why. However, there is
no standard way of expressing such information about a
statement or collection of RDF statements. Named graphs
[94] may solve many of these problems and are already
being employed in projects such as myGrid [95] to trace
data provenance. However, they are not a standard and,
therefore, are not widely supported by Semantic Web
tools.
Lack of a standard rule language
Although there are technologies that enable the use of
rules, there is no standard rule language. This makes it
impossible to write sets of rules that can be used in differ-
ent implementations, limiting the reach of the ACPP
group's vision of distributed clinical guidelines encoded
as rules. We note, however, that the W3C Rule Interchange
Format Working Group [96] is currently working to solve
this problem.
Cross-community interactions
There is an emerging consensus in the bioinformatics
community at large for the need to formalize and share
data annotation semantics. This is championed by such
institutions as the UK e-Science project myGrid [97], the
Bio-Health Informatics Group [98] at the University of
Manchester, U.K., the NIH-funded National Center for
Biomedical Ontology [42,99], and the growing Open Bio-
medical Ontologies (OBO) Foundry [100].
The Semantic Web and biomedical communities need to
further coordinate efforts in areas critical to translational
research, namely:
￿ Formalizing the semantics of the elements of health care
information systems, such as medical records, as well as
clinical decision making, such as disease and symptoms.
￿ Making scientific publishing more effective at support-
ing research communities by finding ways to systemati-BMC Bioinformatics 2007, 8(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/8/S3/S2
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cally capture research results and make them available on
the Semantic Web.
￿ Engaging systems biology researchers as "early adopters"
of Semantic Web technologies, and as a resource for driv-
ing use cases.
￿ Working with natural language processing researchers to
enhance their algorithms with biomedical ontologies, and
to target their output to use terms from established ontol-
ogies.
￿ Working with the U.S. National Library of Medicine
(NLM) to find appropriate ways to translate their exten-
sive vocabularies and knowledge resources into RDF for
effective use on the Semantic Web.
As discussed in [101], tensions have occurred between the
Semantic Web communities and other communities like
the XML and database communities, as some people
believe that the technologies being advocated by these
communities cannot coexist with each other. One way to
ease such tensions is for the Semantic Web community to
develop a complementary rather than competitive rela-
tionship with these communities. The Semantic Web
should be perceived as a complement instead of a replace-
ment to existing technologies. For example, RDF/OWL
can be serialized as XML, and can be used to provide a
richer semantic layer for use with other XML technologies.
The developers of triple stores and RDF query languages
have been greatly inspired by the theoretical and practical
work done by the database community. Providers of valu-
able knowledge such as curators of biological pathways
would be more willing to make their data accessible to the
Semantic Web community if they did not need to aban-
don their own formats. For example, converters can be
provided for translating BioPAX into other pathway data
formats so that tools that were built based on these for-
mats can still be used. At the same time, additional tools
can be developed to exploit the new features (e.g., reason-
ing) enabled by representing BioPAX in OWL.
Education and incentives
The vision of a Semantic Web accelerating biomedical
research crucially depends on the holder of scientific and
clinical data making that data available in a reusable form.
Often the effort that goes into preparing and serving this
data will not directly benefit the provider. Instead,
researchers are measured for producing scientific discover-
ies and writing about them, doctors for helping sick
patients, and pharmaceutical companies for producing
safe, effective drugs. There are also privacy risks involved
with sharing personal information. Valuable patient data
can only be acquired with appropriate consent and with
sensitivity to those privacy issues. It is an open question of
how to structure incentives to make these holders of valu-
able information consider the effort to be in their best
interest.
If the research community decided today that it was moti-
vated to publish data semantically, we do not yet have
adequate numbers of skilled knowledge workers. Data
modelling even without the intention of interoperating is
a hard-learned skill, and the challenge is substantially
magnified when the intention is to share information for
unforeseen uses. We need to establish and populate a new
discipline, a mix of interdisciplinary skills that include
solid understanding of biomedicine, computer science,
philosophy and the social anthropology of science and
computing.
Conclusion
We have discussed the potential of the Semantic Web to
facilitate translational research. Although Semantic Web
technologies are still evolving, there are already existing
standards, technologies, and tools that can be practically
applied to a wide range of biomedical use cases. There are
challenges to the widespread adoption of the Semantic
Web in the health care and life sciences industries. Some
parts of the technology are still in development and are
untested at large scales. Informaticians need training and
support to be able to understand and work with these new
technologies. Incentives need to be provided to encourage
appropriate representation of important research results
on the Web.
By grounding the development and application of this
technology in real concerns and use cases of the biomedi-
cal community, and enabling close interaction between
informaticians, researchers, and clinicians, and the W3C
standards development community, the W3C HCLSIG is
providing a rich collaborative environment within which
to start resolving these issues. The potential of interopera-
ble knowledge sources for biomedicine, at the scale of the
World Wide Web, certainly merits continued attention.
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